Epic C18 Cannabinoid

March 31, 2020



The analysis of cannabinoid samples, to perform complete profiling of the various cannabis and hemp strains and more accurate potency testing, is becoming more essential. There are at least 100 identified cannabinoids that have been isolated from cannabis sativa. These minor cannabinoids can possibly interfere with the chromatography of the five most common cannabinoids: tetrahydrocannabinol (THC), delta-9-tetrahydrocannabinolic acid A (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabinol (CBN). ES Industries Inc. have developed a new C18 column – Epic C18 Cannabinoid to fully resolve the 11 major and most frequently observed minor cannabinoids using commercial standards. The baseline separation achieved with the Epic C18 Cannabinoid column ensures positive identification and accurate quantitation for the cannabinoids of interest. Epic C18 Cannabinoid is based on the robust Epic bonding chemistry developed by ES Industries. The superior performance of Epic C18 Cannabinoid is a product of high density bonding which has been achieved through refinements in the processes and catalyst development. High bonding density is one of the most important factors in producing a robust stationary phase and robust HPLC column. The 11 component cannabinoid analysis is achieved with Epic C18 Cannabinoid using a simple isocratic mobile phase which is more easily transferable between instruments/laboratories, compared to more complex methods that incorporate atypical mobile phase gradients or additives.

ES Industries
701 South Route 73
West Berlin, NJ 08091 USA
856-753-8400
info@esind.comwww.esind.com